REHOVOT, Israel, April 21, 2014 (GLOBE NEWSWIRE) -- Foamix, a clinical-stage, specialty pharmaceutical company, focused on the development, patenting and commercialization of proprietary topical foams and the first topical minocycline/doxycycline antibiotics to address unmet needs in dermatology, today announced that the United States Patent and Trademark Office (“USPTO”) has issued five new patents covering its technologies. Foamix now has a total of 25 issued United States Patents, 61 issued worldwide and 126 patents pending.
Help employers find you! Check out all the jobs and post your resume.
